The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
Open accessAbstract
// Ulrike M. Litzenburger 1,2,* , Christiane A. Opitz 1,2,3,* , Felix Sahm 2,4,5 , Katharina J. Rauschenbach 1,2 , Saskia Trump 6 , Marcus Winter 6 , Martina Ott 1,2 , Katharina Ochs 1,2 , Christian Lutz 7 , Xiangdong Liu 8 , Natasa Anastasov 9 , Irina Lehmann 6 , Thomas Höfer 10 , Andreas von Deimling 4,5 , Wolfgang Wick 1,11 , and Michael Platten 1,2 1 Department of Neurooncology, Neurology Clinic and National Center for Tumor Diseases University Hospital of Heidelberg, Heidelberg, Germany; 2 Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 3 Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), Heidelberg, Germany, 4 Department of Neuropathology, Institute of Pathology, University Hospital of Heidelberg, Germany; 5 Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 6 Department for Environmental Immunology, Helmholtz Center for Environmental Research, Leipzig, Germany, 7 Heidelberg Pharma GmbH, Ladenburg, Germany; 8 Incyte Corporation, Experimental Station, Wilmington, Delaware, USA, 9 Institute of Radiation Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Germany; 10 Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 11 Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany * These authors contributed equally to this work Correspondence: Michael Platten, email: // Christiane Opitz, email: // Keywords : IDO, immunosuppression, autoactivation loop Received : January 13, 2014 Accepted : January 18, 2014 Published : January 20, 2014 Abstract Indoleamine-2,3-dioxygenase (IDO) inhibitors have entered clinical trials based on their ability to restore anti-tumor immunity in preclinical studies. However, the mechanisms leading to constitutive expression of IDO in human tumors are largely unknown. Here we analyzed the pathways mediating constitutive IDO expression in human cancer. IDO-positive tumor cells and tissues showed basal phosphorylation and acetylation of STAT3 as evidenced by western blotting and immunoprecipitation. Inhibition of IL-6 or STAT3 using siRNA and/or pharmacological inhibitors reduced IDO mRNA and protein expression as well as kynurenine formation. In turn, IDO enzymatic activity activated the AHR as shown by the induction of AHR target genes. IDO-mediated AHR activation induced IL-6 expression, while inhibition or knockdown of the AHR reduced IL-6 expression. IDO activity thus sustains its own expression via an autocrine AHR–IL-6–STAT3 signaling loop. Inhibition of the AHR–IL-6–STAT3 signaling loop restored T-cell proliferation in mixed leukocyte reactions performed in the presence of IDO-expressing human cancer cells. Identification of the IDO-AHR-IL-6-STAT3 signaling loop maintaining IDO expression in human cancers reveals novel therapeutic targets for the inhibition of this core pathway promoting immunosuppression of human cancers. The relevance of the IDO-AHR-IL-6-STAT3 transcriptional circuit is underscored by the finding that high expression of its members IDO, STAT3 and the AHR target gene CYP1B1 is associated with reduced relapse-free survival in lung cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Self-citationAn Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T. F. E., Bernd, H.-W., Cogliatti, S. B., Dierlamm, J., Feller, A. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055351 · Cited by 1,006
PrognoScan: a new database for meta-analysis of the prognostic value of genes
Mizuno, H., Kitada, K., Nakai, K., & Sarai, A. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-18 · Cited by 995
Okayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1403 · Cited by 874
Cited by
Rothhammer, V., & Quintana, F. J. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0125-8 · Cited by 1,197
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Regulation of the immune response by the aryl hydrocarbon receptor
Gutiérrez-Vázquez, C., & Quintana, F. J. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.012 · Cited by 985
Aryl hydrocarbon receptor ligands in cancer: friend and foe
Murray, I. A., Patterson, A. D., & Perdew, G. H. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3846 · Cited by 883
Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
Lu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
Self-citationAcetate Production from Glucose and Coupling to Mitochondrial Metabolism in Mammals
Liu, X., Cooper, D. E., Cluntun, A. A., Warmoes, M. O., Zhao, S., Reid, M. A., Liu, J., Lund, P. J., Lopes, M., Garcia, B. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.040 · Cited by 416
Self-citationWirthgen, E., Hoeflich, A., Rebl, A., & Günther, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01957 · Cited by 378
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Théate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.-C., Hervé, C., Gutierrez-Roelens, I., Marbaix, E., Sempoux, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 363
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
Platten, M., von Knebel Doeberitz, N., Oezen, I., Wick, W., & Ochs, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00673 · Cited by 340
Self-citationTrial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Self-citationMolecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 322
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Fujiwara, Y., Kato, S., Nesline, M. K., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102461 · Cited by 304
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Self-citationTryptophan in health and disease
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.08.005 · Cited by 294
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0106-z · Cited by 274
The role of AhR in transcriptional regulation of immune cell development and function
Trikha, P., & Lee, D. A. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188335 · Cited by 96
Kawazoe, A., Kuboki, Y., Shinozaki, E., Hara, H., Nishina, T., Komatsu, Y., Yuki, S., Wakabayashi, M., Nomura, S., Sato, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1803 · Cited by 93
Sonner, J. K., Deumelandt, K., Ott, M., Thomé, C. M., Rauschenbach, K. J., Schulz, S., Munteanu, B., Mohapatra, S., Adam, I., Hofer, A.-C., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240858 · Cited by 64
Metadata
- Authors
- Litzenburger, U. M., Opitz, C. A., Sahm, F., Rauschenbach, K. J., Trump, S., Winter, M., Ott, M., Ochs, K., Lutz, C., Liu, X., Anastasov, N., Lehmann, I., Höfer, T., von Deimling, A., Wick, W., & Platten, M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-01-20
- Volume
- 5
- Issue
- 4
- Pages
- 1038-1051
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2139027624
- Cited by
- 322
- References
- 50
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.